Register for a Biocartis Idylla live demonstration at ASDG Conference
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
02Apr
12Mar
Biocartis announces CE-IVD marking of its Idylla™ MSI Test
Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE[1] colorectal cancer tumor tissue. This CE-IVD launch is a key addition to Biocartis’ colorectal cancer (CRC) Idylla™ test menu as MSI detection is currently recommended for all patients with CRC[2].
28Feb
Streck liquid biopsy-based cancer research webinar
Recent Advances and Challenges in Liquid Biopsy-Based Cancer Research
Abacus dx is happy to be able to present to you a Streck-sponsored on-demand webinar presented by Prof. Dr. med. Stefan Holdenrieder.
25Feb
Idylla EGFR Mutation Test (CE-IVD)
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
20Feb
Register for a live demonstration at RCPA Pathology Update
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
18Feb
ZytoVision FISH Probes for Lung Cancer
ZytoVision’s ZytoLight® products are designed for the identification of genetic aberrations eg. translocations, deletions, amplifications and chromosomal aneuploidies by Fluorescence in situ Hybridisation (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears and metaphase chromosome spreads.
24Jan
Invivoscribe LymphoTrack Dx IVD Assays now available
Abacus dx is pleased to inform you that the Invivoscribe LymphoTrack Dx IVD Assays are now available.
12Dec
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX Genomic Prostate Score® Test.
On the 3rd of December, Genomic Health, Inc and Biocartis Group NV announced that they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version* of the Oncotype DX Genomic Prostate Score® (GPS™) Test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.
28Sep
Asuragen: FragileX
The AmplideX® suite of products is designed to solve unmet testing needs in inherited genetic disorders. The technology overcame a 20-year challenge by reliably amplifying the FMR1 gene. This allowed researchers to gain a deeper understanding of fragile X syndrome, the most common known inherited cause of intellectual disability and autism.